Since the approval of the first biosimilar in Europe more than a decade ago, the use of biosimilars has been increasing in that region. Likewise, the FDA approved the first biosimilar in 2015, and biosimilars have been gaining traction in the United States since then. Nevertheless, for biosimilars to achieve and maintain a strong position in the major pharmaceutical markets, particularly as the competition increases, it is imperative for them to earn the trust of physicians. By elucidating physicians’ decision-making process in the use of biosimilars versus biologics, clients can learn the most important attributes a biosimilar should have. Decision Resources Group conducted primary market research in the United States, France, and Germany with physicians from six specialties to obtain insight into their experiences with and perceptions of biosimilars. In this report, we examine how physicians’ experiences and attitudes compare across specialties and countries and how they have evolved over time.
Questions Answered in This Report:
Markets covered: United States, France, and Germany.
Primary research: Online quantitative survey of 547 physicians from six specialties—endocrinologists, gastroenterologists, nephrologists, rheumatologists, hematology-oncologists, and medical oncologists.